Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer

References

• National Epidemiology CenterCentro Nacional de Epidemiología. Mortalidad por cáncer y otras causas en España; 2013 [Mortality from cancer and other causes in Spain; 2013] Available from: http://www.isciii.es/ISCIII/es/contenidos/fd-servicios-cientifico-tecnicos/fd-vigilancias-alertas/fd-epidemiologia-ambiental-y-cancer/mortalidad-cancer-en-espana.shtmlAccessed March 7, 2016 Spanish
   Google Scholar
• FerlayJBrayFSteliarova-FoucherEFormanDCancer incidence in five continents, CI5plus: IARC cancerbase No. 9Lyon, FranceInternational Agency for Research on Cancer2014 Available from: http://ci5.iarc.frAccessed March 15, 2016
   Google Scholar
• Sánchez de Cos EscuínJMiravet SorribesLAbal ArcaJEstudio multicéntrico epidemiológico-clínico de cáncer de pulmón en España (estudio EpiCliCP-2003) [The EpicliCP-2003 study: a multicenter epidemiological and clinical study of lung cancer in Spain]Arch Bronconeumol2006429446452 Spanish17040660
   PubMed Web of Science ®Google Scholar
• MiravetLParadísAPeláezSArnalMCabadésFEvolución del carcinoma broncopulmonar en el norte de la provincia de Castellón, 1993–2002 [Evolution of lung cancer in the North of the province of Castellón, Spain, 1993–2002]Arch Bronconeumol20044012553557 Spanish15574268
   PubMed Web of Science ®Google Scholar
• MonteroCRosalesMOteroICáncer de pulmón en el área sanitaria de A Coruña: incidencia, abordaje clínico y supervivencia [Lung cancer in the health care area of A Coruña (Spain): incidence, clinical approach and survival]Arch Bronconeumol2003395209216 Spanish12749803
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCSpanish Lung Cancer GroupScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
   PubMed Web of Science ®Google Scholar
• MitsudomiTKosakaTYatabeYBiological and clinical implications of EGFR mutations in lung cancerInt J Clin Oncol200611319019816850125
   PubMedGoogle Scholar
• TarcevaSummary of product characteristics. European Medicines Agency Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000618/human_med_001077.jsp&mid=WC0b01ac058001d124Accessed March 5, 2016
   Google Scholar
• IressaSummary of Product CharacteristicsEuropean Medicines Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001016/WC500036358.pdfAccessed March 5, 2016
   Google Scholar
• GiotrifSummary of Product CharacteristicsEuropean Medicines Agency Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002280/WC500152392.pdfAccessed March 5, 2016
   Google Scholar
• SudaKMizuuchiHMaeharaYMitsudomiTAcquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation – diversity, ductility, and destinyCancer Metastasis Rev2012313–480781422736441
   PubMed Web of Science ®Google Scholar
• HynesNELaneHAERBB receptors and cancer: the complexity of targeted inhibitorsNat Rev Cancer20055534135415864276
   PubMed Web of Science ®Google Scholar
• YangJCWuYLSchulerMAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsLancet Oncol201516214115125589191
   PubMed Web of Science ®Google Scholar
• HaalandBTanPSde CastroGJrLopesGMeta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutationsJ Thorac Oncol20149680581124787964
   PubMed Web of Science ®Google Scholar
• HaspingerERAgustoniFTorriVIs there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutationsCrit Rev Oncol Hematol201594221322725523487
   PubMed Web of Science ®Google Scholar
• LiangWWuXFangWNetwork meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsPLoS One201492e8524524533047
   PubMed Web of Science ®Google Scholar
• PopatSMokTYangJCAfatinib in the treatment of EGFR mutation-positive NSCLC – a network meta-analysisLung Cancer201485223023824929780
   PubMed Web of Science ®Google Scholar
• ZhangYShengJYangYOptimized selection of three major EGFR-TKIs in advanced EGFR-positive non-small cell lung cancer: a network metaanalysisOncotarget2016715200932010826933807
   PubMedGoogle Scholar
• ParkKTanEHO‘ByrneKAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialLancet Oncol201617557758927083334
   PubMed Web of Science ®Google Scholar
• YangJZhouQYanHHA randomized controlled trial of erlotinib versus gefitinib in advanced non-small-cell lung cancer harboring EGFR mutations (CTONG0901)16th World Conference on Lung CancerSeptember 6–9, 2015Denver, CO, USA Abstract 16.13
   Google Scholar
• ZhouCWuYLChenGErlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol201112873574221783417
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLLiuXOverall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl Abstract 7520
   Google Scholar
• SequistLVYangJCYamamotoNPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol201331273327333423816960
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPLUX-Lung 6: a randomized, open label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation positive (EGFR M+) advanced adenocarcinoma of the lungJ Clin Oncol201331Suppl Abstract 8016
   Google Scholar
• RosellRCarcerenyEGervaisRErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
   PubMed Web of Science ®Google Scholar
• WuYLZhouCHuCPAfatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialLancet Oncol201415221322224439929
   PubMed Web of Science ®Google Scholar
• Clinical Trials, 2016aBIBW 2992 (afatinib) versus chemotherapy as first line treatment in NSCLC with EGFR mutation Available from: https://clinicaltrials.gov/ct2/show/results/NCT00949650Accessed April 5, 2016
   Google Scholar
• Clinical Trials, 2016bBIBW 2992 (Afatinib) vs gemcitabine-cisplatin in 1st line Non-small Cell Lung Cancer (NSCLC) Available from: https://clinicaltrials.gov/ct2/show/results/NCT01121393?sect=X3n0156#evntAccessed April 5, 2016
   Google Scholar
• BotPlus 2.0General Council of Official Colleges of Pharmacists Available from: https://botplusweb.portalfarma.com/Accessed April 20, 2016 Spanish
   Google Scholar
• IslaDGonzález-RojasNNievesDBrosaMFinnernHWTreatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panelClin Transl Oncol201113746047121775273
   PubMed Web of Science ®Google Scholar
• Llibre-CodinaJMCasado-GómezMASánchez-de la RosaRCoste de la toxicidad asociada a los análogos de nucleósidos inhibidores de la transcriptasa inversa en pacientes con infección por el VIH-1 [Cost of nucleoside analogue reverse transcriptase inhibitor-related toxicity in HIV-1-infected patients]Enferm Infecc Microbiol Clin200725298107 Spanish17288907
   PubMed Web of Science ®Google Scholar
• OjedaBde SandeLMCasadoAMerinoPCasadoMACost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in SpainBr J Cancer20038961002100712966416
   PubMed Web of Science ®Google Scholar
• Rubio-TerrésCCoboESacristánJAPrietoLdel LlanoJBadíaXGrupo ECOMEDAnalysis of uncertainty in the economic assessment of health interventionsMed Clín (Barc)200412217668674 Spanish15153348
   PubMed Web of Science ®Google Scholar
• BriggsAClaxtonKSculpherMDecision Modelling for Health Economic EvaluationOxford, UKOxford University Press2006
   Google Scholar
• García-CampeloRBernabéRSEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015Clin Transl Oncol201517121020102926691657
   PubMed Web of Science ®Google Scholar
• JansenJPTrikalinosTCappelleriJCDawJAndesSEldessoukiRSalantiGIndirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force reportValue Health201417215717324636374
   PubMed Web of Science ®Google Scholar
• NysoeTEPaauwDSSymptom managementBartlettJGCheeverLWJohnsonMPPaauwDSA Guide to Primary Care of People with HIV/AIDSRockville, MAU.S. Department of Health and Human Services200455
   Google Scholar
• National Institute for Health and Care ExcellenceGuide to the Methods of Technology Appraisal2013 Available from: https://www.nice.org.uk/article/pmg9/resources/non-guidance-guide-to-the-methods-of-technology-appraisal-2013-pdfAccessed April 19, 2016
   Google Scholar